His primary areas of study are Internal medicine, Surgery, Placebo, Crohn's disease and Gastroenterology. His Ulcerative colitis, Inflammatory bowel disease, Adverse effect, Infliximab and Maintenance therapy investigations are all subjects of Internal medicine research. Within one scientific family, Brian G. Feagan focuses on topics pertaining to Etrolizumab under Surgery, and may sometimes address concerns connected to Phases of clinical research.
Brian G. Feagan has researched Placebo in several fields, including Clinical endpoint, Randomized controlled trial, Clinical trial and Induction chemotherapy. His work focuses on many connections between Crohn's disease and other disciplines, such as Severity of illness, that overlap with his field of interest in Visual analogue scale and Pathology. The Gastroenterology study combines topics in areas such as Pharmacokinetics, Vedolizumab, Crohn's Disease Activity Index, Gastrointestinal agent and C-reactive protein.
His main research concerns Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. His Internal medicine research includes elements of Placebo and Surgery. His research integrates issues of Adverse effect, Randomized controlled trial and Maintenance therapy in his study of Placebo.
His Crohn's disease study integrates concerns from other disciplines, such as Physical therapy, Clinical trial, Certolizumab pegol and Ustekinumab. His study in Ulcerative colitis is interdisciplinary in nature, drawing from both Colitis and Adalimumab, Golimumab, Infliximab. His studies deal with areas such as Gastrointestinal agent, Quality of life, Immunology and Intensive care medicine as well as Inflammatory bowel disease.
Internal medicine, Ulcerative colitis, Gastroenterology, Crohn's disease and Inflammatory bowel disease are his primary areas of study. Brian G. Feagan regularly ties together related areas like Placebo in his Internal medicine studies. Brian G. Feagan has included themes like Meta-analysis, Randomized controlled trial and Maintenance therapy in his Placebo study.
His research investigates the link between Ulcerative colitis and topics such as Confidence interval that cross with problems in Odds ratio. His Gastroenterology research incorporates elements of Clinical endpoint, Induction therapy, Calprotectin and Ozanimod. Brian G. Feagan works mostly in the field of Crohn's disease, limiting it down to topics relating to Post-hoc analysis and, in certain cases, Immunosuppression, as a part of the same area of interest.
Brian G. Feagan mostly deals with Internal medicine, Crohn's disease, Ulcerative colitis, Placebo and Gastroenterology. His study in Randomized controlled trial, Vedolizumab, Clinical trial, Adverse effect and Crohn's Disease Activity Index falls under the purview of Internal medicine. His biological study spans a wide range of topics, including Hazard ratio, Prospective cohort study, Radiology and C-reactive protein.
His Ulcerative colitis research includes themes of Odds ratio, Tofacitinib, Colitis, Inflammatory bowel disease and Receiver operating characteristic. The various areas that Brian G. Feagan examines in his Placebo study include Infliximab, Ustekinumab, Confidence interval, Meta-analysis and Endoscopy. His Gastroenterology study combines topics from a wide range of disciplines, such as Biomarker, Clinical endpoint, Maintenance therapy and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey.
The New England Journal of Medicine (2004)
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)
Certolizumab pegol for the treatment of Crohn’s disease:
William J. Sandborn;Brian G. Feagan;Simeon Stoinov;Pieter J. Honiball.
The New England Journal of Medicine (2007)
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
Geert D’Haens;William J. Sandborn;Brian G. Feagan;Karel Geboes.
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
Geert D'Haens;Filip Baert;Gert van Assche;Philip Caenepeel.
The Lancet (2008)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Paul Rutgeerts;Brian G. Feagan;Gary R. Lichtenstein;Lloyd F. Mayer.
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: